Amir Fathi, MD, Massachusetts General Hospital

home / authors / amir-fathi,-md,-massachusetts-general-hospital

Articles

Optimizing Treatment Selection for Patients with FLT3-ITD AML

Optimizing Treatment Selection for Patients with FLT3-ITD AML

Naval G. Daver, MD;Amir Fathi, MD, Massachusetts General Hospital;Margaret T. Kasner, MD;Eunice Wang, MD, Roswell Park Comprehensive Cancer Center
July 24th 2023

Discussion centered around optimal strategies to effectively treat, and improve outcomes for, patients with FLT3-ITD AML.

Read More

Standard Approach to Treatment for Fit Patients with Newly Diagnosed AML

Standard Approach to Treatment for Fit Patients with Newly Diagnosed AML

Naval G. Daver, MD;Amir Fathi, MD, Massachusetts General Hospital;Margaret T. Kasner, MD;Eunice Wang, MD, Roswell Park Comprehensive Cancer Center
July 17th 2023

Recommendations for community oncologists concerning the treatment of fit patients diagnosed with AML.

Read More

Clinical Insights Concerning Molecular Testing in Patients Diagnosed with Acute Myeloid Leukemia

Clinical Insights Concerning Molecular Testing in Patients Diagnosed with Acute Myeloid Leukemia

Naval G. Daver, MD;Amir Fathi, MD, Massachusetts General Hospital;Margaret T. Kasner, MD;Eunice Wang, MD, Roswell Park Comprehensive Cancer Center
July 17th 2023

Eunice S. Wang, MD opens a discussion with other panelists concerning the benefits of germline testing in AML, NCCN guidelines for molecular testing, and how molecular testing in AML is advancing over time.

Read More

Expert on AML

Activity, Tolerability and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed or Refractory NPM1-Mutated AML

Amir Fathi, MD, Massachusetts General Hospital
July 12th 2023

Expert Amir Fathi, MD, reviews recent clinical data with ziftomenib in patients with relapsed/refractory acute myeloid leukemia.

Read More

An Introduction to Biomarker Testing in Acute Myeloid Leukemia

An Introduction to Biomarker Testing in Acute Myeloid Leukemia

Naval G. Daver, MD;Amir Fathi, MD, Massachusetts General Hospital;Margaret T. Kasner, MD;Eunice Wang, MD, Roswell Park Comprehensive Cancer Center
June 26th 2023

Experienced clinicians highlight the role of biomarker testing in AML for optimal patient care and treatment selection.

Read More

An Overview of Incidence, Diagnosis, and Subtype Classification in Acute Myeloid Leukemia

An Overview of Incidence, Diagnosis, and Subtype Classification in Acute Myeloid Leukemia

Naval G. Daver, MD;Amir Fathi, MD, Massachusetts General Hospital;Margaret T. Kasner, MD;Eunice Wang, MD, Roswell Park Comprehensive Cancer Center
June 26th 2023

Moderator Naval G. Daver, MD introduces expert panelists and leads an overview of Acute Myeloid Leukemia, focusing on the importance of timely diagnosis and risk assessment for patients with AML.

Read More

Progress in the Treatment of AML

Progress in the Treatment of AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

Implications for Treating AML With CC-486

Implications for Treating AML With CC-486

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

CC-486 Maintenance Therapy in AML

CC-486 Maintenance Therapy in AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

Gemtuzumab for AML

Gemtuzumab for AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

CPX-351 in Newly Diagnosed Secondary AML

CPX-351 in Newly Diagnosed Secondary AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

Differentiation Syndrome and IDH Inhibitors in AML

Differentiation Syndrome and IDH Inhibitors in AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

IDH Inhibitors and MDS

IDH Inhibitors and MDS

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

IDH1/2 Inhibitors for AML

IDH1/2 Inhibitors for AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

IDH Mutations in AML

IDH Mutations in AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

FLT3 Triplet Regimens for AML

FLT3 Triplet Regimens for AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

Monitoring Response to Venetoclax Regimens in AML

Monitoring Response to Venetoclax Regimens in AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

Venetoclax in AML: Safety Profile

Venetoclax in AML: Safety Profile

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

Optimal Use of Venetoclax in AML

Optimal Use of Venetoclax in AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

VIALE Studies in AML

VIALE Studies in AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

Utilization of Second-Generation FLT3 Inhibitors in AML

Utilization of Second-Generation FLT3 Inhibitors in AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

Second-Generation FLT3 Inhibitors in AML

Second-Generation FLT3 Inhibitors in AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

FLT3-Mutated AML: Midostaurin and Chemotherapy

FLT3-Mutated AML: Midostaurin and Chemotherapy

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

FLT3-Mutated AML: Early Aggressive Therapy vs Transplant

FLT3-Mutated AML: Early Aggressive Therapy vs Transplant

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

FLT3 Genetic Alterations in AML

FLT3 Genetic Alterations in AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need